On January 6, 2026 AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, reported it will attend the 44th Annual J.P. Morgan Healthcare Conference on January 12-15, 2026 in San Francisco, CA, and host meetings showcasing the Company’s recent accomplishments and sharing strategic plans moving forward. The Company’s Chairman and CEO, Tony (Bizuo) Liu, has also been invited as a panel speaker at the Conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Session:

Emerging Biotechs from China

Time & Date:

January 14, 2026, 16:30 – 17:15 PST

Location:

Pacific Hall, Convene, 40 O’Farrell St, San Francisco

Description:

China is emerging as a hub of global biotech innovation. Leveraging on strong capability in early discovery
and clinical resources, China’s biotech companies are joining the global innovation in the next wave of oncology and
autoimmune assets. In this panel, J.P. Morgan invited CEOs with lead assets in cell therapy and other modalities and will
discuss differentiation of their assets and strategy for business developments

(Press release, AbelZeta, JAN 6, 2026, View Source [SID1234661774])